Drug Trial Radar · NCT06886516
Apixaban in Thrombocytopenia
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Feb 28, 2025
Primary completion
Jul 1, 2027
Study completion Jul 1, 2029
Sponsor
- Lead sponsor
- Rushad PatellAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)
Conditions
- Deep Vein Thrombosis
- Pulmonary Embolism and Thrombosis
- Thrombocytopenia
- Recurrent Venous Thromboembolism
Interventions
ApixabanDrug
A factor Xa inhibitor, 2.5 and 5 mg tablets, by mouth per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study EnrollmentTime frame: Up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.